Publicacións en colaboración con investigadores/as de Instituto de Salud Carlos III (328)

2026

  1. Corrigendum to ‘FABP4, marker of worse prognosis in cardiovascular disease, induces neutrophil’s proatherogenic phenotype which is modulated by semaglutide’(Journal of Molecular and Cellular Cardiology, (2026), 210, C, (12-27), (S0022282825001932), 10.1016/j.yjmcc.2025.10.009)

    Journal of Molecular and Cellular Cardiology

  2. FABP4, marker of worse prognosis in cardiovascular disease, induces neutrophil's proatherogenic phenotype which is modulated by semaglutide

    Journal of Molecular and Cellular Cardiology, Vol. 210, pp. 12-27

2025

  1. Absence of MCJ/DnaJC15 promotes brown adipose tissue thermogenesis

    Nature communications, Vol. 16, Núm. 1, pp. 229

  2. Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction

    The New England journal of medicine, Vol. 393, Núm. 19, pp. 1889-1900

  3. Carvedilol versus flecainide treatment in idiopathic ventricular extrasystoles and tachycardias (CARFLECT IV) trial: Rationale and design

    Revista Portuguesa de Cardiologia, Vol. 44, Núm. 12, pp. 709-715

  4. Conceptos anatómicos fundamentales

    Anatomía humana para estudiantes de Ciencias de la Salud (Elsevier), pp. 1-10

  5. Continuity of primary care and its impact on prognosis in patients with heart failure referred for cardiology consultation

    BMC Primary Care, Vol. 26, Núm. 1

  6. Coronary sinus unroofing associated with congenitally corrected transposition of the great arteries: a case report

    European Heart Journal - Case Reports, Vol. 9, Núm. 2

  7. Differential effect of triglycerides on the prognosis of patients with a first versus recurrent acute coronary syndrome

    European Journal of Clinical Investigation, Vol. 55, Núm. 10

  8. Effects of GLP-1 agonists on 10-year cardiovascular risk reduction in primary prevention: A 44-week open label prospective study

    Diabetes and Metabolic Syndrome: Clinical Research and Reviews, Vol. 19, Núm. 9

  9. Epigenetic regulation of electromechanical continuity might determine phenotypic heterogeneity in SCN5A mutation carriers in Brugada syndrome

    Scientific Reports, Vol. 15, Núm. 1

  10. Estimate and prognosis of patients who are candidates for treatment with eicosapentaenoic acid after an acute coronary syndrome

    Journal of Clinical Lipidology, Vol. 19, Núm. 4, pp. 827-834

  11. Evaluation of carbohydrate antigen 125 in heart failure with preserved ejection fraction diagnosis

    Heart

  12. Factors Predicting Myocardial Recovery After Hospitalization for De Novo Heart Failure with Reduced Left Ventricular Ejection Fraction: Results from the COMFE Registry

    Biomedicines, Vol. 13, Núm. 5

  13. Gender-specific effects of delay in cardiology consultation following primary care physician referral in atrial fibrillation patients: Impact on one-year outcomes

    International Journal of Cardiology, Vol. 422

  14. Genome-wide analyses identify 30 loci associated with obsessive–compulsive disorder

    Nature Genetics, Vol. 57, Núm. 6, pp. 1389-1401

  15. Linking genomic and proteomic signatures to brain amyloid burden: insights from GR@ACE/DEGESCO

    Functional and Integrative Genomics, Vol. 25, Núm. 1

  16. Meteorin-like protein plasma levels are associated with worse outcomes in de novo heart failure

    European Journal of Clinical Investigation, Vol. 55, Núm. 4

  17. Multiparametric assessment of atrial cardiopathy in cryptogenic stroke patients: Implications for personalized clinical management

    European Stroke Journal

  18. NT-proBNP in Acute De Novo Heart Failure: A Key Biomarker for Predicting Myocardial Recovery—COMFE Registry

    Life, Vol. 15, Núm. 4